HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose genetic activation of MAPK as a resistance mechanis...

Full description

Bibliographic Details
Main Authors: Alison E. Smith, Emanuela Ferraro, Anton Safonov, Cristina Bernado Morales, Enrique J. Arenas Lahuerta, Qing Li, Amanda Kulick, Dara Ross, David B. Solit, Elisa de Stanchina, Jorge Reis-Filho, Neal Rosen, Joaquín Arribas, Pedram Razavi, Sarat Chandarlapaty
Format: Article
Language:English
Published: Nature Portfolio 2021-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-27093-y

Internet

https://doi.org/10.1038/s41467-021-27093-y

Similar Items